-
New research out of New York found the protection of the vaccine against infection in kids who got the lowest dose dropped from 68% to 12%.
-
The consensus has been that Pfizer and Moderna are most protective. But a study looking at 5 vaccines — including Russia's Sputnik V and two Chinese types — offers an unexpected finding.
-
Some countries are moving ahead with plans to offer a fourth dose of COVID-19 vaccine. But studies are raising questions about the potential advantages of this extra booster.
-
Though people who are vaccinated and boosted appear to be better protected against omicron, the highly contagious variant has still led to breakthrough cases and a surge in infections worldwide.
-
The new recommendation for adolescents age 12-17 came hours after a panel of CDC advisers voted in favor of it. The boosters should be given five months after initial immunization.
-
The authorization comes in the midst of an explosion of COVID-19 cases nationwide driven by the omicron variant — a surge that has brought a spike in pediatric hospitalizations.
-
The new at-home COVID treatment is currently available in limited quantities to states and territories. Some states will get as few as 120 courses of treatment at first.
-
Pfizer and BioNTech, which produced the first COVID-19 vaccine authorized in the U.S., say they will expand ongoing trials to include a third dose for children as young as 6 months old.
-
The research finds that the medicine, called Paxlovid, was effective in preventing hospitalization and death when taken by people with mild to moderate illness within a few days of symptoms.
-
Pfizer's CEO says the vaccine maker has asked federal regulators to authorize boosters for 16- and 17-year-olds. Currently, only people 18 and over are eligible for a booster in the U.S.
-
The Food and Drug Administration is expected to announce later this week that it is authorizing boosters for people 18 or older, even if they aren't at risk for severe disease.
-
The agreement covers 95 nations, but it omits hard-hit countries such as Russia, Turkey, Brazil, and Mexico. Pfizer said it is seeking authorization for emergency use of the medication in the U.S.